Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Open access
Parsons, Heather A., Rhoades, Justin, Reed, Sarah C., Gydush, Gregory, Ram, Priyanka, Exman, Pedro, Xiong, Kan, Lo, Christopher C., Li, Tianyu, Fleharty, Mark, Kirkner, Gregory J., Rotem, Denisse, Cohen, Ofir, Yu, Fangyan, Fitarelli-Kiehl, Mariana, Leong, Ka Wai, Hughes, Melissa E., Rosenberg, Shoshana M., Collins, Laura C., Miller, Kathy D., Blumenstiel, Brendan, Trippa, Lorenzo, Cibulskis, Carrie, Neuberg, Donna S., DeFelice, Matthew, Freeman, Samuel S., Lennon, Niall J., Wagle, Nikhil, Ha, Gavin, Stover, Daniel G., Choudhury, Atish D., Getz, Gad, Winer, Eric P., Meyerson, Matthew, Lin, Nancy U., Krop, Ian, Love, J. Christopher, Makrigiorgos, G. Mike, Partridge, Ann H., Mayer, Erica L., Golub, Todd R., Adalsteinsson, Viktor A. · 2020 · Clinical Cancer Research

Abstract

Purpose: Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1,000-fold lower error rate than conventional sequencing. Experimental Design: We compared the sensitivity of our approach to digital droplet PCR (ddPCR) in a dilution series, then retrospectively identified two cohorts of patients who had undergone prospective plasma sampling and clinical data collection: 16 patients with ER+/HER2− metastatic breast cancer (MBC) sampled within 6 months following metastatic diagnosis and 142 patients with stage 0 to III breast cancer who received curative-intent treatment with most sampled at surgery and 1 year postoperative. We performed whole-exome sequencing of tumors and designed individualized MRD tests, which we applied to serial cfDNA samples. Results: Our approach was 100-fold more sensitive than ddPCR when tracking 488 mutations, but most patients had fewer identifiable tumor mutations to track in cfDNA (median = 57; range = 2–346). Clinical sensitivity was 81% (n = 13/16) in newly diagnosed MBC, 23% (n = 7/30) at postoperative and 19% (n = 6/32) at 1 year in early-stage disease, and highest in patients with the most tumor mutations available to track. MRD detection at 1 year was strongly associated with distant recurrence [HR = 20.8; 95% confidence interval, 7.3–58.9]. Median lead time from first positive sample to recurrence was 18.9 months (range = 3.4–39.2 months). Conclusions: Tracking large numbers of individualized tumor mutations in cfDNA can improve MRD detection, but its sensitivity is driven by the number of tumor mutations available to track.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-3005

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 193

Metadata

Authors
Parsons, H. A., Rhoades, J., Reed, S. C., Gydush, G., Ram, P., Exman, P., Xiong, K., Lo, C. C., Li, T., Fleharty, M., Kirkner, G. J., Rotem, D., Cohen, O., Yu, F., Fitarelli-Kiehl, M., Leong, K. W., Hughes, M. E., Rosenberg, S. M., Collins, L. C., Miller, K. D., Blumenstiel, B., Trippa, L., Cibulskis, C., Neuberg, D. S., DeFelice, M., Freeman, S. S., Lennon, N. J., Wagle, N., Ha, G., Stover, D. G., Choudhury, A. D., Getz, G., Winer, E. P., Meyerson, M., Lin, N. U., Krop, I., Love, J. C., Makrigiorgos, G. M., Partridge, A. H., Mayer, E. L., Golub, T. R., & Adalsteinsson, V. A.
Venue
Clinical Cancer Research
Published
2020-06-01
Volume
26
Issue
11
Pages
2556-2564
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3012499484
Cited by
193
References
3
FWCI
7.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-3005
The paper
Parsons, H. A., Rhoades, J., Reed, S. C., Gydush, G., Ram, P., Exman, P., Xiong, K., Lo, C. C., Li, T., Fleharty, M., Kirkner, G. J., Rotem, D., Cohen, O., Yu, F., Fitarelli-Kiehl, M., Leong, K. W., Hughes, M. E., Rosenberg, S. M., Collins, L. C., . . . Adalsteinsson, V. A. (2020). Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-3005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.